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Background
Adenovirus serotype 26 (Ad26) is a rare Ad serotype that
differs substantially from Ad5 in terms of baseline sero-
prevalence, receptor usage, tropism, innate immune pro-
file, adaptive immune phenotype, and protective efficacy
in the SIV/macaque model.  Here we report the initial
safety and immunogenicity assessment of a prototype
Ad26 vector in humans.
Methods
Ad26 expressing the VRC EnvA test antigen was manufac-
tured by Crucell.  36 Ad26 seronegative, healthy subjects
were enrolled in a randomized, double-blinded, placebo-
controlled, dose-escalation phase 1 study.  Groups of 12
subjects received doses of 109, 1010, or 1011 vp of the
Ad26-EnvA vector (N=10/group) or placebo (N=2/group)
at weeks 0, 4, and 24.  We performed a pre-specified
blinded immunogenicity analysis after the first two
immunizations.  Validated IFN-gamma ELISPOT assays
were performed with positivity criteria of >55 SFC/106
PBMC and >4-fold background.
Results
26/36 subjects were female, and 70/72 vaccinations were
administered.  Some reactogenicity was observed after the
initial immunization in the highest dose group but typi-
cally resolved within 24 h.  No vaccine-associated AEs or
SAEs occurred.  In all three dose groups, 2 subjects/group
exhibited no detectable vector- or insert-specific immune
responses at any timepoint, whereas 10 subjects/group
developed positive Ad26 NAb titers, EnvA-specific ELISA
titers, and EnvA-specific ELISPOT responses following
vaccination.  In the 109 vp dose group, the median ELISA
titer was 1000 (IQR 300-3,000) and the median ELISPOT
response was 381 SFC/106 PBMC (IQR 125-545) at week
8.  In the 1011 vp dose group, the median ELISA titer was
5,477 (IQR 3,000-10,000) and the median ELISPOT
response was 365 SFC/106 PBMC (IQR 85-715) at week
8.
Conclusion
The Ad26 vector is safe and immunogenic in humans at
all three doses.  Ad26 is therefore a promising new vector
for further clinical studies to evaluate novel inserts such as
mosaic HIV-1 Gag, Pol, Env antigens.
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